Key information

🔎 Fund Overview

Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform to enable it to connect alpha-particle emitting isotopes to various targeting molecules to selectively deliver the alpha-particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals; its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, and its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging diagnostics. Its lead product candidate, FPI-1434, utilizes its Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), with actinium-225 or 225Ac.